Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients
Open Access
- 6 October 2021
- journal article
- review article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 156 (1) , 33-48
Abstract
Introduction: Despite advances in modern medicine, brain tumor patients are still monitored purely by clinical evaluation and imaging. Traditionally, invasive strategies such as open or stereotactic biopsies have been used to confirm the etiology of clinical and imaging changes. Liquid biopsies can enable physicians to noninvasively analyze the evolution of a tumor and a patient’s response to specific treatments. However, as a consequence of biology and the current limitations in detection methods, no blood or cerebrospinal fluid (CSF) brain tumor-derived biomarkers are used in routine clinical practice. Enhancing the presence of tumor biomarkers in blood and CSF via brain-blood barrier (BBB) disruption with MRI-guided focused ultrasound (MRgFUS) is a very compelling strategy for future management of brain tumor patients. Methods: A literature review on MRgFUS-enabled brain tumor liquid biopsy was performed using Medline/Pubmed databases and clinical trial registries. Results: The therapeutic applications of MRgFUS to target brain tumors have been under intense investigation. At high-intensity, MRgFUS can ablate brain tumors and target tissues, which needs to be balanced with the increased risk for damage to surrounding normal structures. At lower-intensity and pulsed-frequency, MRgFUS may be able to disrupt the BBB transiently. Thus, while facilitating intratumoral or parenchymal access to standard or novel therapeutics, BBB disruption with MRgFUS has opened the possibility of enhanced detection of brain tumor-derived biomarkers. Conclusions: In this review, we describe the concept of MRgFUS-enabled brain tumor liquid biopsy and present the available preclinical evidence, ongoing clinical trials, limitations, and future directions of this application.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (5R25NS065729, 1R21NS113016-01)
This publication has 117 references indexed in Scilit:
- Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patientsJournal of Applied Genetics, 2013
- A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuroprotective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian MonkeysPLOS ONE, 2012
- Insights into pediatric diffuse intrinsic pontine glioma through proteomic analysis of cerebrospinal fluidNeuro-Oncology, 2012
- A Spontaneous Mutation in Contactin 1 in the MousePLOS ONE, 2011
- Targeted Delivery of Neural Stem Cells to the Brain Using MRI-Guided Focused Ultrasound to Disrupt the Blood-Brain BarrierPLOS ONE, 2011
- Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various gradesNeuro-Oncology, 2010
- A strategy for blood biomarker amplification and localization using ultrasoundProceedings of the National Academy of Sciences, 2009
- Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkersNature Cell Biology, 2008
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005